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This thesis was written in a rather turbulent time 
During which I wondered why bother my mind 
By writing a silly little scientific book 
In which very few will actually look 
But at least it gave my mind some ease 
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in which my attention was merely focused on this thesis. You always knew when I said that I 
was almost done, that I was nowhere near the end, yet I was met with nothing but kindness, 




Ewing sarcoma (ES) is a rare and aggressive childhood/adolescent malignancy which relies 
on a multidisciplinary treatment approach for cure. The overall survival rate for this young 
patient group has hardly improved over the last 30 years despite large multinational treatment 
trials. Thus, there are important research questions to be answered with regards to systemic 
treatment. However, this thesis is about local treatment. Local treatment is indisputably 
important for overall survival, yet we have not reached a consensus for which local treatment 
regime is best for the individual patient. Therefore, local treatment is always a matter of 
debate on multidisciplinary meetings in sarcoma centers around the world. In the national 
multidisciplinary sarcoma conferences hosted at the Karolinska University Hospital every 
fortnight, every ES case in the country is brought up for discussion and there is an 
unproportioned amount of time spent on each case compared to other sarcomas. Due to the 
rare nature of this disease, randomized trials on local treatment are unlikely to occur and local 
treatment relies on case series and studies hampered by low number of patients. This thesis 
aims to shed light on the following questions: (1) which is the optimal local treatment 
strategy for pelvic ES; (2) how are ES of the spine treated in Scandinavia and what is the 
neurologic and oncologic outcome; (3) what is the true risk for subsequent primary 
neoplasms (SPNs) among ES survivors and (4) what is the effect of local treatment on local 
failure, long term mortality and morbidity?  
Study 1 evaluates different local treatment options in treatment of pelvic ES and whether 
local control of sacral ES can be achieved with radiotherapy alone. Innominate bone ES were 
in most cases treated surgically and sacral bone tumors were largely treated with radiotherapy 
(RT) alone. We found that sacral site was an independently favorable site as regards disease-
free survival compared with the innominate bones. Furthermore, good local control could be 
obtained with RT alone for tumors located in the sacrum. 
Study 2 investigated if the same good outcome found among ES of the sacrum could be seen 
among patients with ES of the mobile spine. Additionally, the neurologic deficits at time of 
diagnosis and at end of follow-up for ES of the mobile spine were examined in relation to 
local treatment. Only 24 patients with sufficient data were found eligible for the analysis. 
Neurologic deficits at presentation were common which often led to emergency 
decompression before having a histopathologic diagnosis. Emergency decompression was 
associated with a higher rate of local failure. Most patients recovered neurologically 
regardless of local treatment, perhaps because of prompt initiation of systemic treatment 
leading to tumor shrinkage and less pressure on the spinal cord. Disease-free survival was 
relatively favorable, but perhaps not as good as that of sacral ES. As was the case with sacral 
ES, the majority of patient were treated with RT exclusively which reflects the difficulties in 
performing “en bloc” surgery in this site. Local control was excellent for the few patients 
with tumors manageable by surgery. 
 
 
Study 3 investigated the risk for secondary malignancies among Ewing- and osteosarcoma 
(OS) survivors in a population-based nationwide cohort. ES survivors had double the risk of 
OS survivors, and a four times higher risk than the general population of acquiring an SPN. 
The excess risk was largely driven by breast cancer and female genital malignancies for ES as 
well as OS survivors, and not as much by secondary sarcoma as anticipated. Due to the high 
background breast cancer incidence in the general population, the excess breast cancer risk 
among ES survivors translates to 127 extra breast cancers per 10 000 person years. The 
excess cancer risk remained elevated with increasing follow-up and over calendar time. 
Study 4 evaluated the role of surgery and RT in relation to surgical margin and local control. 
Secondarily, the effect of local treatment on long-term mortality, occurrence of SPN and 
hospitalization was studied. Local treatment had a significant effect not only on local failure, 
but also on overall survival. Surgical treatment gave superior local control compared with 
definitive RT. The lowest local failure rate was achieved if surgery was performed with a 
wide surgical margin. Nonetheless, RT also played a significant role with regards to local 
control since marginally resected tumors treated with adjuvant RT achieved an equal local 
control rate to that of a wide margin. This is a key finding because accomplishing a wide 
surgical margin is rarely possible for tumors located in the pelvis or spine, sites which 
comprise a third of all ES.  
In conclusion, tumor site is an important prognostic factor in ES. Pelvic and spinal sites pose 
a specific challenge since surgery of the primary tumor is less often performed due to the 
morbidity associated with surgery in these sites. Hence, more patients will receive definitive 
RT. Definitive RT seems to achieve good local control for tumors of the sacrum. 
Nevertheless, the long-term results of definitive RT are unknown. For tumors located in sites 
other than the sacrum, surgery is superior to definitive RT in achieving local control and 
improving survival. Moreover, best local control is achieved when surgery is carried out with 
wide margins, in which case RT does not improve outcome. Importantly, radiotherapy 
improves local control for marginally resected tumors.  
The long-term excess risks for SPNs are mainly driven by breast cancer among females. 
Unfortunately, the risks remain high in recent treatment periods. Moreover, the excess risk 
persists with extended follow-up, indicating the need for lifelong surveillance and tailored 
follow-up. However, the outcome after local recurrence is dismal. The benefit of 
administering RT when indicated must therefore not be overshadowed by the risk for 
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Ewing sarcoma (ES), first described as diffuse endothelioma of bone by James Ewing in 
1921, is an aggressive form of sarcoma formerly referred to as Ewing's family of tumors 
(ESFT)
1
. EFTS was previously differentiated into classic Ewing's sarcoma, Askin tumor 
(Ewing sarcoma of the chest wall), and peripheral primitive neuroectodermal tumor (PNET). 
The term PNET and Askins tumor is no longer in use, and the group of tumors are now 
simply classified as Ewing sarcomas
2
. Before chemotherapy was introduced in the 1970s, 
around 90 % of Ewing sarcoma patients died
3
. Today, around 65-75 % of patients without 
detectable metastatic disease at time of diagnosis will survive. Nevertheless, the improvement 
in survival has plateaued out and the prognosis for the 1/4 of patients who present with 




Sarcomas are a group of heterogeneous aggressive malignancies that arise in tissues of 
mesenchymal origin, including muscle, fat, cartilage and bone. The incidence in Europe is 5-
6 /100 000 per year
5




Ewing sarcoma is the second most common bone sarcoma after osteosarcoma among 
children and adolescents, with an annual incidence of 1-3 persons per million
8,9
. There is a 
slight male predominance and the incidence is much higher among Caucasians than among 
Afroamericans and Asians
10
.  Around a quarter of ES arise in soft tissue rather than in bone. 
A quarter of all skeletal ES occurs in the pelvis, and around 20 % occurs in the femur
11-13
. If 
arising in the long bones, the tumor is typically located in the diaphysis. The most prevailing 
metastatic site are the lungs (50%) followed by bone (25%) and bone marrow (20%)
11,14
. 
Seventy percent of the patients are younger than 20 years of age, with a median age at 
diagnosis between 14 and 17 years
11,13,15
.  
Clinical presentation and diagnosis 
Typically, the patients present with pain and swelling, and it is not uncommon with a history 
of trauma around the onset of diagnosis. The duration of symptoms prior to the first medical 
visit is over 6 months
16
. Patients occasionally have systemic changes such as fever or weight 
loss. A plain x-ray will usually lead to a high suspicion of a primary bone malignancy. 
Furthermore, an MRI of the tumor including the whole compartment is performed to 
determine the extent of bone and soft tissue involvement. Frequently, there will be a 
significant soft tissue component of which relation to the vessels and nerves is of central 
importance when planning for biopsy and local treatment.  
 
2 
Definitive diagnosis is established through biopsy, either fine-needle, core-needle or open. 
Morphologically, ES appears as an undifferentiated small round blue-cell malignancy. 
Mitotic index is low. The surface antigen MIC2 (CD99) can be found in over 90% of tumors, 
and ES cells ordinarily stain positive for periodic acid–Schiff (PAS) and vimentin
17
. 
Molecular diagnosis is of particular importance in the diagnosis of ES since 85 % of Ewing 
sarcomas carry a specific t(11;22) translocation resulting in an EWS-FLI1 fusion transcript. 
The remaining 15 % of cases that do not have the EWS-FLI1 fusion gene, will have the EWS 
gene fused to another member of the ETS family of genes, such as ERG, ETV1, or E1AF
14
. 
Molecular analysis using fluorescent in-situ hybridization (FISH) or reverse transcript PCR 
(RT-PCR) to detect the fusion gene, has been a routine part of the diagnosis of ES in 
Scandinavia since the end of the nineties.  
Computer tomography of the chest is performed as part of the staging procedure in order to 
screen for lung metastases. Detection of bone metastases is traditionally done with bone 
scintigraphy. However, [
18
F]fluorodeoxyglucose positron emission tomography (FDG-PET) 
or a fusion PET-CT is becoming a routine part of staging procedures in many centers. 
Curiously, the proportion of patients presenting with clinically evident metastasis has stayed 




Systemic treatment  
Combination chemotherapy has significantly enhanced the survival rates of patients with 
localized disease from 10% to around 75%
14,18
. However, it has had little effect on patients 
who present with metastasis. For this group of patients, overall survival at 5 years is less than 
30%. Furthermore, for patients who suffer from relapse, the 5-year event-free survival rate is 
only 10%
19,20
. The standard treatment algorithm today is neoadjuvant multi-agent 
chemotherapy for at least 12 weeks followed by local treatment which consists of surgery or 
radiotherapy or a combination of the two. Thereafter, maintenance chemotherapy is given for 
a period of time ranging from 25-37weeks. The duration and type of chemotherapy given 
during the maintenance period depends on the tumor response to chemotherapy and the risk 
profile of the patient. Most patients are included in multinational studies comparing different 
maintenance treatments. The standard induction chemotherapy treatment in Europe today 
consists of 6 cycles of VIDE (vincristine, ifosfamide, doxorubicin and etoposide), whereas in 
North America VDC-IE (vincristine, doxorubicin, cyclophosphamide-ifosfamide and 
etoposide) given at a compressed interval is the standard. A recently closed trial (Euro-Ewing 
2012) aims to compare which of these regimens is the better. Furthermore, the use of high 
dose chemotherapy and stem cell rescue has shown a favorable effect in some studies, while 







It is well known that ES is a radiosensitive tumor. Initially, surgical treatment was therefore 
confined to expandable bones, but as surgical techniques evolved, surgical treatment 
indications extended. Growing endoprostheses, allografts and vascularized autografts have all 
improved functional outcome and enabled limb sparing surgery. Despite advancements in 
surgical treatment, complications such as post-operative infection, endoprosthetic loosening 
and bone healing difficulties are common in this young and active patient group.  
Radiotherapy on the other hand has fewer early complications, but serious late effects are a 
problem, becoming increasingly evident as the number of long-term survivors is increasing. 
The long-term side effects of radiotherapy include growth impairment, insufficiency fractures 
and most importantly a significantly increased risk for secondary malignancies.  
Available data favor surgery over definitive radiotherapy in the local treatment of ES
24-33
. The 
indications for post-operative radiotherapy are debatable, but most would agree for its 
indication in the setting of an intralesional, or perhaps a marginal surgical margin
26,33
. 
The current recommendation regarding local treatment of ES is therefore surgical resection 
with a wide margin. Surgical treatment or radiotherapy is rarely a matter of debate when the 
primary tumor is located in the extremities. However, given the fact that a third of all ES are 
located in the pelvis and spine, one can certainly imagine that that the issue of the best 
primary local treatment is quite often debated at multidisciplinary tumor meetings around the 
world
13
. The discussion usually comes down to whether the tumor can be excised with a clear 
(wide or marginal) margin, preferably a wide one, without significant morbidity. Since almost 
all tumors can be resected with a clear margin regardless of location if the associated 
morbidity and loss of function is ignored, the definition of an acceptable surgical morbidity is 
debatable and individualized. A pelvic tumor in proximity to the acetabulum can in most 
circumstances be excised and reconstructed with an acceptable risk for complications and a 
good functional outcome. Most specialists would probably opt for surgery in such a case, but 
how about a pelvic tumor that would require a hindquarter amputation; is that an acceptable 
surgical outcome that would outweigh the benefits of surgery over radiation treatment? What 
is the actual benefit of surgery over RT as regards to local control? 
Custom made pelvic endoprosthesis, the use of large allografts, autografts and excision and 
extracorporeal irradiation or cryotherapy and re-implantation are all evolving techniques 
which have improved the arsenal of reconstructive options in recent years. Therefore, the idea 
of what is an operable tumor and what is not may have shifted over time. Furthermore, the 
negative long-term effects of the alternative local treatment; definite radiotherapy, are 
becoming evident as the number of long-term survivors is increasing. This has led to different 
local treatment strategies in North America and Europe, with more restricted use of RT in 
North America. 
A randomized study comparing radiotherapy and surgery does not seem feasible
33
. Therefore, 
there is a demand for good retrospective studies examining the oncological outcome as well 








The overall aim of this thesis was to study the role of local treatment on local failure and late 
morbidity. Ultimately, the purpose was to understand which parameters the most important 
when choosing the most appropriate local treatment for the individual patient. The specific 
aims were: 
-to study if sacral ES are treated differently and whether they have a worse oncologic 
outcome compared with ES elsewhere in the bony pelvis. 
-to study the clinical presentation of spinal ES and how local treatment affects the oncologic 
outcome.  
-to evaluate the role of surgery, radiotherapy (RT) or the combined treatment on the risk for 
local failure and disease relapse. 
 
-to delineate the importance of surgical margin with regards to local control. 
 
-to investigate the long-term risk and time trends for subsequent primary neoplasms (SPN) 





3 MATERIALS AND METHODS 
This thesis is based on registries and review of individual medical records. The first two 
papers were based on the Scandinavian Sarcoma Registry (SSG); the third paper was based 
on the Swedish Cancer Register. In the last paper, the cohort was comprised of ES patients 
identified in the Swedish Pediatric Cancer Registry, which was linked with the SSG registry, 
the Swedish Cancer Register, the Death Cause Register and the National Patient Register.   
3.1 THE REGISTRIES 
The Scandinavian Sarcoma registry, which strangely enough contains data on patients from 
Sweden, Norway and Finland, was established in 1986. It was initially started by orthopedic 
sarcoma surgeons and later extended to include data provided by visceral sarcoma surgeons. 
The registry is therefore very surgically oriented with robust data, prospectively collected on 
parameters believed to be important for a surgeon such as surgical margin, tumor location, 
tumor size, type of reconstruction performed after excision and above all on local recurrence. 
Information on chemotherapy and radiotherapy is not as sound and there are no data on 
complications and side effects. Therefore, many individual medical records had to be 
reviewed in study I and for all cases in study II. The data in the registry were found to be very 
reliable with regards to local recurrence and metastasis when compared with the medical 
charts that were reviewed. The disadvantage of the registry is that the completeness of the 
registry is not as good. Pediatric sarcoma doctors report to their “own” registry, the Swedish 
Pediatric Cancer Registry, some of the pediatric sarcoma cases are therefore unknown to the 
SSG registry. The SSG registry has been administered by the Scandinavian Sarcoma Group 
up to 2018, when the Regional Cancer Centers (RCC) included the sarcoma register to a 
common platform for cancer quality registers (INCA) run by the National Board of Health 
and Welfare. There is therefore no longer a Scandinavian registry, instead independent 
national registries. Close collaboration between the Scandinavian countries still exists, but the 
exchange of data between Scandinavian countries has become increasingly troublesome after 
the European General Data Protection Regulation (GDPR) was introduced.  
The Swedish Pediatric Cancer Registry was initiated by pediatric oncologists in the 1970-ies, 
which saw the need for gathering treatment information on leukemia patients in order to 
evaluate which treatments were working
34
. The registry expanded to other childhood 
malignancies and became nationwide including basically all pediatric malignancies occurring 
in Sweden since 1982. The completeness of the registry is good, but it contains only pediatric 
patients and follow-up is lost after the patients turn 18 and are transferred to adult oncology 
departments. Because it has always been run by pediatricians, the registry is more oncologic 
oriented with more detailed data on chemotherapy than on variables such as type of 
reconstruction after surgical excision.  Nevertheless, the registry contains very detailed 
information on treatment, which of course is essential for evaluating complications and side 
effects caused by the treatment. The registry does not include structured information on late-
effects, but late- effects are often commented on in the registry indicating that pediatric 
oncologists have always shown a strong interest for this issue, an interest that has become a 
 
8 
very important research area in recent years. The problem with registering late-effects lies in 
the above mentioned fact, that pediatric patients are transferred to adult health care after the 
age of 18. Some patients are even lost to regularly follow-up and turn up in other medical 
institutions with complications related their primary treatment. The complications may be 
unknown to the treating physician because they range broadly across disciplines, such as 
cardiovascular, endocrinology or musculoskeletal. The registry is currently administered by 
the Karolinska Institute, and there is ongoing work aimed at transferring data to a national 
database for all care and research on cancer.  
The Swedish Cancer Register is a nationwide population-based registry founded in 1958
35
. 
The methods of registration in the Register are very well described in numerous publications 
and the completeness of the Register is over 94%
36
. It is mandatory by every health care 
provider to report on every new cancer case. Registration relies on dual reporting, as the 
pathologist as well as the treating physician has to report new cases. Even malignancies 
diagnosed at autopsy are registered. There is a very strong organization involved in 
confirming and correcting the Register, which is run by the Swedish National Board of 
Health and Welfare through six regional oncologic centers throughout Sweden. Coding of a 
new malignancy in the Register is based on internationally accepted rules for classification of 
cancer established by the International Association of Cancer Registries (IACR) and 
International Agency for Research on Cancer (IARC). A few benign tumors such as 
meningioma and other benign tumors of the central nervous system are also classified in the 
Swedish Cancer Register, due to their potentially aggressive clinical course. Notifications to 
the registry are also done for papillomas of the lower urinary tract, due to the known 
difficulty of ascertaining the malignant potential of lower urinary tract tumors. Skin cancers 
reported to the registry include malignant melanoma and squamous cell carcinoma 
exclusively; basal cell carcinomas are not registered. Tumors in the Swedish Cancer Register 
are all classified according to tumor site, as stated by the International Classification of 
Diseases, seventh edition (ICD-7). Codes reported in newer versions of the classification 
system (ICD-8, ICD-9 and ICD-10) are automatically recoded into ICD-7 codes. The 
histological tumor type is recorded according to ICD-O/2 and ICD-O/3 since 1993 and 2005, 
respectively. For the whole period from 1958 to the present, the codes are also available as 
historic histology codes (WHO/HS/CANC/24.1). The strength of the registry is also its 
weakness; only a few patient parameters are registered such as patient age, gender and place 
of residence. Medical data includes site, morphology, tumor stage, date of diagnosis, 
reporting institution and identification number for each specimen. Follow-up is limited to the 
death date, cause of death and date of migration. Data on treatment are completely lacking. 
The National Patient Register was started in 1960, initially including only 16 percent of 
patients treated in somatic in-patient care, but all in-patients treated in psychiatric care. Since 
1984 the Ministry of Health and Welfare made it compulsory by all councils to participate, 
and since 1987 it includes all in-patient care in Sweden, public and private. Data reported 
from the different councils are updated monthly and underreporting is very low. The Register 
contains data on age, gender, place of residence, date of admission and discharge, length of 
 
 9 
hospital stay, where the patient was admitted from and where the patient was discharged to. 
The medical data includes the main diagnosis corresponding to an ICD code, additional 
diagnosis and surgical procedures. Quality controls on the submitted data are performed 




The Death Cause Register is also administered by the National Board of Health and Welfare. 
The Register contains date of death, the main cause of death and the illness leading to death 




The cohort analyzed in paper 1 was extracted from the Scandinavian Sarcoma Group registry. 
It included only ES patients diagnosed with a primary tumor in the bony pelvis between 1986 
and 2011. The bony pelvis consists of two bones: the sacrum and the hip bone/innominate 
bone. The latter consisting of three bones: the ilium, ischium and the pubic bones. The cohort 
comprised patients from Sweden, Norway and Finland. One hundred and twenty-one patients 
were identified in the registry. Three patients were excluded because of loss to follow-up; all 
with primary tumors in the innominate bone. One patient with a tumor in the sacrum was 
excluded due to insufficient information on the primary treatment. In the final analysis there 
were 88 and 29 patients in the innominate- and sacrum group respectively. Medical records 
were reviewed in detail if the data of interest could not be extracted from the registry. 
The Scandinavian Sarcoma Group registry was also used for identifying the cohort in paper 
2. All patients with a primary ES tumor located in the mobile spine (from the 1
st
 cervical to 
the 5
th
 lumbar vertebra) diagnosed between 1986 and 2012, and with a minimum follow-up of 
2 years were included. One patient was excluded because the spinal tumor was not believed 
to be a primary tumor, but rather a metastasis. In the final analysis there were 24 patients. All 
medical records were reviewed in order to obtain the relevant clinical data.  
The cohort studied for paper 3 consisted of ES and osteosarcoma patients identified in the 
Swedish Cancer Register from 1958 through December 31
st
 2015. Only patients with tumors 
of the extremities, trunk or chest wall were included. Time at risk started at time of primary 
bone sarcoma diagnosis and continued until the occurrence of a new primary neoplasm or 
until death or end of follow-up. Four individuals had identical morphology codes for the 
primary bone sarcoma and the subsequent primary neoplasm. Three of these patients, had a 
primary OS and were diagnosed with a subsequently occurring OS within 24 months. One 
patient with a primary ES suffered from a subsequent tumor classified as a new ES. These 4 
patients were thus either misclassified or considered as having synchronous or metachronous 
OS/ES. Synchronous (at time of diagnosis) or metachronous (separated in time) OS, defined 
as 2 or more skeletal lesions occurring without the presence of lung metastasis, is observed 
among patients with predisposing syndromes. It constitutes a controversial issue because it is 
unknown if synchronous or metachronous lesions are clonally unrelated tumors or skeletal 
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metastasis from the primary OS. The 4 patients identified in this cohort were excluded due to 
this uncertainty. In the final analysis, there were 1779 patients; 1201 OS and 578 ES patients.  
Paper 4 included 229 patients with a Ewing family of tumor were identified in the Swedish 
Child Cancer Register from January 1
st
 1982 until June 1
st
 2017. All ES patients (not 
restricted to extremities, trunk or torso) were analyzed. Therefore, the cohort included 
patients with tumors in the head and neck region, which are treated by ear nose throat tumor 
surgeons, as well. The register classifies tumors according the WHO-2005 International 
Classification of Childhood Cancer (ICCC-3), which is a slightly different classification 
system than the previously described registries. Indeed, the ICCC-3 is also based on ICD-O-3 
histology and ICD-O-2/3. The Swedish Cancer Register was linked with the SSG registry, the 
Cancer Register, the Death Cause Register and the Patient Register, a linkage that is possible 
due to each individual’s unique personal identification number. Linkage with the latter 
registers was not possible for 26 of the patients identified in the Swedish Cancer Register. For 
some, the reason was that the patients had emigrated to Sweden and either had a temporary 
personal identification number or had changed their personal identification number, for others 
it was unknown why the individuals were not registered in the other registers. Nevertheless, 
data on these individuals only registered in the Swedish Cancer register were good; hence 
they were not excluded from the analysis. Furthermore, latest time of follow-up in the Cancer 
Register and Patient Register was December 31
st
 2015, while latest follow-up in the 
Scandinavian Sarcoma registry was February 18
th
 2015. Consequently, the analysis requiring 
data from the latter registers does not include the 26 patients identified exclusively in the 





3.2 ETHICAL ASPECTS 
The Nuremberg code is the basic guideline for the legislation linked to ethics in Sweden. All 
medical research involving human subjects follow the ethical principles stated in the 
declaration of Helsinki. All registries used in this thesis were approved by the Swedish Data 
Inspection Board and follow the Swedish legislation, which includes the Swedish Personal 
Data Act, the Swedish Patient Data Act and, since May 2018, the European General Data 
Protection Regulation. Patients are informed that registration in a national registry will take 
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3.3 DIAGNOSIS AND TREATMENT 
3.3.1 Diagnosis 
The diagnosis of ES is based on morphology consistent with a CD-99 positive 
undifferentiated small round blue-cell tumor and a molecular translocation analysis 
demonstrating the EWSR fusion transcript. The fusion transcript, which is considered 
mandatory for the diagnosis to be made, has been in routine use in Scandinavia since 1999. 
Prior to 1999, the diagnosis was established based on morphology alone. However, almost all 
ES patients in Scandinavia have been included in different international trials, which require 
the histology to be peer-reviewed by an expert musculoskeletal tumor pathology board. Any 
patient with histology consistent with ES, Askin´s tumor or pNET (primitive 
neuroectodermal tumor) of bone and soft tissue, was included in this analysis. 
3.3.2 Systemic treatment 
Because the ES patients studied in this thesis in large were enrolled in different ongoing 
trials, they received chemotherapy protocols mainly depending on which study they were 
enrolled in. The patients in the cohorts of study I and II received chemotherapy according to 
Scandinavian or collaborative Scandinavian-Italian protocols. Patients diagnosed between 
1984 and 1990 were treated according to the SSG IV protocol, from 1990 to 1999 with the 
SSG IX protocol and from 1999 up to current day with the SSG/Italian Sarcoma Group (ISG) 
protocol. Before these study periods ES patients were treated solely with surgery, RT or the 
combination of both.  
ES patients treated in pediatric centers in Sweden were primarily enrolled in,- or at least 
treated according to, the protocols in pan European studies such as the Euro-E.W.I.N.G-99, 
Euro Ewing 2012 or the joint European-North American Ewing 2008. Unlike the ES patients 
of cohorts I and II, the cohort in study IV was treated according to the pediatric Ewing 
protocols above. The chemotherapy administered across the different protocols use the same 
drugs in different constellations; Vincristine, Ifosfamide, Doxorubicin, Etoposide, 
Cyclophosphamide and Actinomycin D. High dose treatment and stem cell rescue or 
autologous bone transplantation was included in the EuroEwing trials as well as the SSG/ISG 
trials. 
3.3.3 Local treatment 
For non-metastatic ES, the SSG/ISG protocols recommended surgery with wide margins after 
induction chemotherapy. The SSG/ISG III and IV protocols, which was the basis for most 
patients in study I and II, were very specific. Excision was recommended for all tumors 
located in bones that do not require reconstruction after excision; clavicle, rib, scapula, iliac 
wing, pubic rami, but also for tumors in the pelvis and long bones that require reconstruction 
such as the humerus, distal radius, proximal ulna, femur and tibia. Amputation was 
recommended when the functional deficit caused by radiotherapy would be greater than that 
after amputation, typically that would include the following two situations: children under the 
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age of 8 with a tumor involving a major growth plate where radiation would cause a severe 
limb length discrepancy or a patient with a pathological fracture. For children under the age 
of 10 with lesions of the proximal and distal femur, rotation plasty was advocated
39
.  
If surgery resulted in inadequate margins (intralesional or marginal), regardless of 
chemotherapy response, the recommendation was to administer RT in full doses of 42 or 54 
Gy. Radiotherapy alone was reserved for tumors, which because of site or size exclude the 
possibility of surgery with adequate margins. Radiotherapy was administered in a hyper 
fractionated and accelerated fashion in order to shorten treatment time and to achieve the 
maximum effect with the least long-term side effect by superimposing chemotherapy and RT. 
RT was administered at the beginning of the consolidation treatment. The EuroEwing 
protocols are less detailed with regards to recommendations on local treatment.  
3.3.4 Surgical margin 
Surgical margin was based on Enneking´s classification. Intralesional margin was defined as 
a procedure resulting in the tumor being transected or opened during surgery. The definition 
of a marginal margin was when the closest margin was outside the tumor, but close to the 
tumor and transecting the reactive zone. A surgical procedure resulting in a wide margin was 
achieved when there was a cuff of healthy tissue surrounding the specimen and covering the 





Investigation performed after end of treatment included a set of mandatory examinations; 
complete physical examination, complete blood count, serum creatinine, GFR, electrolytes, 
LDH, ALP and liver transaminases. The radiologic requirements during follow-up were x-ray 
of the chest and the entire involved bone, CT and MRI scans over the entire involved bone 
(except for patients who had undergone reconstruction with metal implants) and cardiac 
ultrasound. 
Follow-up for pediatric patients was done in the pediatric oncology department every 3 
months for the first 3 years, thereafter at 4 month intervals for another 2 years and thereafter 
biannually up to 10 years. Children were transferred to the adult oncology clinic when they 
turned 18; otherwise regularly follow-ups were terminated 10 years after end of treatment. 
However, in recent treatment periods, pediatric patients in Sweden have been followed even 
past 10 years in so called late-effect clinics.  
At each follow-up the following investigations were done; physical examination, chest X-ray, 
blood count, transaminases, ALP, LDH and serum creatinine. Glomerular filtration rate 
(GFR) every 6 months, cardiac ultrasound at 3 months, 6 months and then every 3 years after 
treatment. ECG was recommended every 3 years after treatment as well as a sperm count for 
males. The radiologic examinations performed at each follow-up were x-rays of the entire 
involved bone and of the chest. A CT of the chest was recommended if lung metastases were 
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suspected on the chest x-ray and a bone scan was recommended if bone metastases were 
suspected.    
3.3.6 Statistics 
In study I and II, the categorical parameters were studied for statistical significance by the use 
of the chi-square test. The continuous variables were analyzed using the student-t test. The 
statistical tests for significance were two sided and a p-value <0.05 was considered 
significant. The method of Kaplan-Meier was used to investigate the rate of local recurrence, 
relapse (local or distant) or death. The time from diagnosis until occurrence of any of the 
events mentioned above or end of follow-up was used for the Kaplan-Meier estimates. The 
log-rank test was used to test the statistical significance of each variable with regards to the 
outcomes studied. Variables considered to be statistical significant for each end point were 
entered into a Cox proportional hazards model, and if they contributed significantly to the fit 
of the model, they were included in the analysis. A fixed covariate model was assumed 
because none of the variables were believed to be time-dependent.  
In study III, standardized incidence ratios and absolute excess risks were used to investigate 
the risk for SPNs in the study population compared to the general population. Incidence rates 
in the study group were matched with regards to age-, sex- and calendar year of diagnosis- 
with the population based incidence rates retrieved from the National Board of Health and 
Welfare in order to calculate the standardized incidence rates (SIRs). The number of expected 
cancer cases was calculated by multiplying the Swedish incidence rates by the total person-
time at risk for each stratum in the cohort. The standardized incidence ratios were calculated 
by dividing the observed number of cases with the expected number of cases. Overall and 
SPN-specific incidence ratios were estimated and stratified by sex, age at diagnosis (0-9, 10-
19 and >20 year intervals), follow-up (0-5, 5-30 and >30 year intervals), calendar year at 
diagnosis (1958-1979, 1980-1999 and 2000-2015) and site of primary tumor. The rationale 
for dividing age at diagnosis into the intervals as stated above was that we assumed that the 
risk for certain SPNs was higher the younger the patients were at the time of treatment (e.g. 
that the risk for RT- or chemotherapy related sarcoma would be greatest if administered to the 
growing child). The age group 10-19 years was chosen to include all girls treated during 
puberty, a period in which the breast tissue proliferate the most. We could have divided the 
age groups even more, but this would have been at the expense of less power as the number 
of patients in each group would have been smaller. Age at time of diagnosis had been 
reported in earlier studies as an important host-related risk factor
40,41
.  The intervals chosen to 
subgroup patients according to calendar year at diagnosis were based on time periods 
corresponding to major changes in treatment. Nineteen fifty eight to 1979 corresponds to the 
pre chemotherapy- or first generation chemotherapy era, 1980-1999 is the era in which 
combination chemotherapy was introduced for ES as well as for OS patients. In the modern 
treatment era (2000-2015), perhaps more restricted use of RT due to the increased awareness 
of late effects would be reflected in a lower risk for SPNs. 
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The absolute excess risk (AER) was calculated by subtracting the expected number of SPNs 
from the observed number of SPNs divided by person-years at risk multiplied by 10 000. The 
Confidence Intervals (CIs) were calculated assuming that the number of observed cases of 
SPN followed a Poisson distribution. We also estimated the overall cumulative SPN 
incidence in an analysis limited to our cohort. Because patients with a history of malignancy 
prior to their ES or OS diagnosis were believed to represent a subgroup with an inherent 
increased cancer risk, we also did an analysis excluding this patient group to see if this altered 
the results found in the initial analysis.  
In study IV, tests for statistical differences at baseline between the local treatment groups 
were done with the use of the chi square- and the Independent samples Kruskal-Wallis test 
for categorical and continuous variables respectively. The method of Kaplan-Meier was used 
to estimate the local recurrence- and overall survival rates for the different exposures studied. 
Time at risk started at time of diagnosis and ended at time of an event or end of follow-up. 
Differences in hospital admittance and hospital stay between the treatment groups were tested 
with the Independent samples Mann-Whitney U-test. All tests were two sided and the 
significance level was set to p<0.05. 
4 RESULTS 
4.1 DISEASE FAILURE IN PELVIC EWING SARCOMA DEPENDS ON 
WHETHER THE TUMOR IS LOCATED IN THE SACRUM OR INNOMINATE 
BONE (HIP BONE) (STUDY I) 
Study I was conducted after a clinical observation by a senior colleague who had noticed a 
seemingly low local and distant failure rate in patients with sacral ES. Patients with ES 
elsewhere in the bony pelvis were studied as a control group. Bear in mind that ES of the 
pelvis is indisputably associated with a poor prognosis. 
Patient demographics were similar for patients with tumors located in the sacrum and in the 
innominate bone. However, tumor characteristics differed with regards to tumor size. 
Measured in the largest diameter, ES of the innominate bone were in average 2 cm larger 
than sacral ES (p<0.05).  
As predicted, we found that patients with tumors of the innominate bone received more 
aggressive local treated than patients with tumors of the sacrum. Only 17% of patients with 
sacral ES had surgery or surgery with radiotherapy, whereas 56% of patients with tumors 
located in the innominate bone underwent surgery +/- radiotherapy. Four patients in the 
innominate bone group and one patient in the sacrum group received only systemic therapy.  
Twenty-five patients of surgically treated patients received adjuvant radiotherapy. Fourteen 
of these patients received post-operative and 8 patients received pre-operative radiotherapy. 
For 3 patients, it was unknown how RT was administered. Of patients who underwent post-
operative radiotherapy, only two had a wide surgical margin, the remaining had intralesional 
or marginal margins. 
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Of the 49 surgically treated patients in the innominate bone group, a clear surgical margin 
was achieved for 42 (86%) of the patients. Only 1/5 surgically treated patient in the sacral site 
group had a wide surgical margin.     
For patients with a minimum follow-up of 2 years, there was only 1(4%) local failure in the 
sacrum group and 9 (11%) local failures in the innominate bone group. The median time to 
local failure was 2 years.  
Disease-free survival was significantly better for patients with tumors located in the sacrum 
compared with patients with tumors located in the innominate bones (P<0.05).  
 
Fig.1 Disease-free survival analysis of 117 pelvic Ewing sarcomas showing cumulative 5-
year disease-free survival rates of 66% and 40% for sacral and innominate bone tumors 
respectively. Log rank p=0.01. With permission from JB&JS. 
The overall median time to event was 16 months (range 155 months). 
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In the univariate analysis of tumor characteristic- or treatment related parameters being 
associated with the occurrence of any event (local failure, distal failure or death), the absence 
of metastasis at diagnosis, tumor size < 8 cm and sacral tumor site were significantly 
favorable clinical parameters (surgical treatment showed a trend for being a positive 
prognostic factor, p=0.07). The cut-off for large and small tumors of 8 cm was based on 
previous studies and staging systems, in which a large tumor (> 8 cm) places the patient in a 
different stage, associated with a higher risk for disease failure. A tumor diameter of 8 cm 
corresponds to a tumor volume of slightly more than 200 ml. In the multivariate cox 
regression analysis, tumor size was no longer a significant prognostic factor for disease-free 
survival. Sacral site on the contrary, remained a significantly favorable prognostic factor 
(Table 1).  
Table 1. Multivariate Disease-Free Survival Analysis   
Variable HR 95 % CI  P-value 
Site (Sacrum) 0.34 0.14 to 0.84 0.02 
Tumor Size   
(continous) 
1.02  0.96 to 1.10 0.50 
Metastasis at time of 
diagnosis 
2.68 1.42 to 5.08  0.002 
Abbreviations: HR=hazard ratio, CI=Confidence Interval 
 
Regarding overall survival, there was a trend for an improved survival for patients with 
tumors in a sacral site compared with innominate bone site (overall survival rate of 65 % and 
49% for sacral and innominate bone tumors respectively, p=0.08). Inferior overall survival 
was observed for patients with metastasis at diagnosis, tumor size > 8 cm, positive surgical 
margin and local recurrence. In the multivariate analysis, only metastasis at diagnosis (HR, 
2.04, 95% CI, 1.04-4.01) and local recurrence (HR, 2.68; 95% CI, 1.09-6.6) significantly 
affected overall survival, although surgical margin was omitted from the analysis due to the 
low number of patients treated in the group of patients with sacral tumor site. 
The role of postoperative radiotherapy in correlation to surgical margin is demonstrated in 
Fig 2 and Fig 3. Supplementing surgery with radiotherapy for patients with marginal or 
intralesional surgical margin significantly improved the overall survival rate to a rate equal to 




Fig 2 showing the cumulative overall survival of patients with intralesional or marginal 
margin without radiation treatment compared to patients with intralesional or marginal 






Fig 3 showing the cumulative overall survival of patients with wide margin without radiation 
treatment compared to patients with intralesional or marginal margin with post op radiation 
treatment. Log rank p=0.91. With permission from JB&JS. 
Metastasis at presentation was common among patients with tumors in the sacrum (41%) as 
well as among patients with tumors in the innominate bone (38%), although as many as 33% 
were alive 5 years after diagnosis.  
4.1.1 Conclusion 
Radiotherapy alone seems to give good local control in patients with ES of the sacrum. For 
patients with tumors elsewhere in the bony pelvis, surgery should be the treatment of choice, 
and if a wide surgical margin is not achieved, radiotherapy should be administered. Sacral 
site itself appears to be a favorable prognostic factor compared with other pelvic sites, for 
reasons that cannot be explained by this study.  
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4.2 DISEASE FAILURE AND NEUROLOGIC SYMPTOMS AMONG PATIENTS 
WITH EWING SARCOMA OF THE MOBILE SPINE (STUDYII) 
Based on the results of study I where we demonstrated that sacral site (fixed spine) was a 
positive prognostic factor and that radiotherapy alone provided good local control, we 
conducted study II to investigate if the same favorable local control rate and overall survival 
rate could be shown among patients with tumors in the mobile spine. Twenty-four patients 
were included in this study. 
As was observed among patients with ES of the fixed spine (sacrum) in study I, the majority 
(18/24) of patients with ES of the mobile spine were also treated with definitive RT. The 
median radiation dose among patients treated with radiotherapy alone was 51.5 Gy. Six 
patients underwent surgery, of which 4 also received RT post-operatively. Three out of 6 
patients had clear resection margins. Nineteen out of 23 patients presented with neurologic 
symptoms of which 9 patients were treated with urgent decompressive surgery without 
excision of the tumor. Two patients underwent urgent laminectomy and simultaneous tumor 
excision, while 2 patients received chemotherapy prior to a complete tumor excision and 
laminectomy.  
There were 5 local recurrences, one of which occurred as long as 10 years after diagnosis. 
The local recurrence rate was thus 27% at 10 years (in comparison, for innominate bone- and 
sacral tumors, the 10-year local recurrence rate was 15% and 5 % respectively). None of the 6 
patients treated surgically experienced a local recurrence; however there was no statistical 
difference in local recurrence rate between patients treated with definitive radiotherapy or 
surgery (p=0.12). Only treatment era had a significant impact on local failure as there were no 
local failures from1999-present. However, performing urgent decompressive surgery showed 
a tendency to increase the local failure rate (p=0.06). 
The 5 year disease-free survival rate was 54% (the disease-free survival rates for patients with 
tumors in the innominate bone and sacrum were 40% and 65%, respectively). The overall 
survival rate was 63% (65% and 49% for sacral and innominate bone tumors respectively). 
Treatment era (p=0.02) and performing decompressive surgery (p=0.05) had a significant 
effect on disease failure in the univariate analysis, although neither (p=0.06 for 
decompressive surgery) were significant in the multivariate analysis.   
Excisional surgery (p=0.05) and local failure (p=0.01) had a significant effect on overall 





Neurologic deficits due to spinal cord compression/injury were classified according to the 
Frankel scale (Fig 4).  
Fig 4 
Frankel scale 
A Absent motor and sensory function 
B No motor function, but some sensation below level of lesion 
C Sensation present. Some motor function without practical application 
(grade 2-3/5) 
D Sensation present. Useful motor function below level of lesion (grade 
4/5) 
E Normal sensation and motor function  
 
Of the 19 patients that presented with neurologic deficits, the majority was Frankel grade D. 
Four out of 6 and 9/13 patients who were treated with radiotherapy and surgery respectively 
had complete neurologic recovery at latest follow-up (Frankel grade E). Among patients with 
neurologic sequelae, all were able to walk (Frankel grade D). 
Serious surgical late complications requiring revision surgery occurred in 5/13 patients, 3 of 
which were due to kyphotic deformities. Five late complications were related to 
chemotherapy, and 1 patient with a C6 tumor treated with radiotherapy suffered severe 
esophageal strictures requiring repeated esophageal dilatation and a percutaneous endoscopic 
gastrostomy. 
4.2.1 Conclusion 
Patients with ES located to the mobile spine are generally treated with definitive radiotherapy 
which results in a relatively high local failure rate. Neurologic symptoms at presentation are 
common, which often leads to urgent spinal decompression and contamination of tumor in 
the surgical wound. We saw a tendency for a higher failure rate among patients treated with 
urgent spinal decompression. As neurologic recovery was good regardless of whether or not 
spinal decompression was performed, urgent spinal decompression without excision of the 
tumor should be avoided if possible. If laminectomy is performed, posterior stabilization 
should be considered to minimize the risk for later spinal gibbus deformity. Furthermore, 
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improved local control was seen in the recent treatment era, perhaps due to improved 
systemic treatment. 
4.3 RISK PATTERNS FOR SUBSEQUENT PRIMARY NEOPLASMS AMONG 
BONE SARCOMA SURVIVORS (STUDY III) 
The risk for secondary cancer or subsequent primary neoplasms (SPNs) has shown great 
variation in previous uncontrolled studies. The rationale for the current study was to assess 
the overall risk for SPNs among bone sarcoma (Ewing and osteosarcoma) survivors and to 
delineate the risk pattern, e.g. which specific SPN are survivors at risk for; which age group 
are at highest risk; has the risk been reduced in recent treatment eras and for how long does 
the increased risk persist in comparison to the risk in the general population 
From 1958 until December 31
st
 2015, 115 SPNs were observed among 104 individuals 
previously diagnosed with an ES or osteosarcoma. Sixteen patients had more than 1 SPN. 
Eighty six patients were diagnosed with a malignancy prior to the bone sarcoma diagnosis. 
This was much more common among osteosarcoma patients (7%) than among ES patients 
(1%) (p=0.001). 
ES survivors were more than four times as likely to experience a SPN than the general 
population and twice as likely as OS survivors to experience a SPN (SIR 4.2; 95% CI 2.8–6.1 
and SIR 1.9; 95% CI, 1.5–2.4, for Ewing- and osteosarcoma survivors respectively). For ES 
survivors, a more than 7-fold risk increase was observed in the age group 10-19 years at age 
of diagnosis (95% CI, 4.2–11.6). Among OS survivors, the highest risk was observed in the 
youngest patient group (0-9 years of age) who also showed a nearly 7-fold risk increase 




Fig 5. showing SIRs by age at diagnosis for ES and OS survivors. 
The highest risk with regards to anatomic site was observed among ES survivors with a 
primary tumor in the pelvis who demonstrated a nearly 8-fold increased risk compared with 
the general population (95% CI, 2.1–19.4). By treatment era, the risk remained the same for 
patients treated in the first and last treatment era (SIR 1958-1979 2.0; 95% CI, 1.5–2.6 and SIR 
2000–2015 2.0; 95%CI, 1.1–3.5) (Fig 6). The 30 year cumulative SPN risk was 7% and 9% for 




Fig 6 showing SIRs for SPN by year of diagnosis. 
Ewing sarcoma survivors were nearly 5 times as likely to develop a breast cancer  compared 
with the general population and OS survivors more than twice as likely, making breast cancer 
the largest driver of excess cancer risk among ES as well as OS survivors (95% CI, 1.7–10.2 
and 1.1–3.6 for ES and OS survivors respectively). The overall increased risk for breast 
cancer remained higher than expected for survivors with more than 30 years of follow-up 
(SIR 2.6; 95% CI, 1.0–5.7). Due to the high background breast cancer incidence in the 
general population, the elevated risk translates to an excess of 13 breast cancers for every 
1000 person-years of follow-up. By anatomic site, 12 times more SPNs than expected were 
observed among ES survivors with a central but not pelvic location of the primary tumor 
(95% CI, 2.4–34.0). Overall, survivors with a central location of the primary tumor had a 7-
fold higher breast cancer risk, while survivors with a tumor in the extremities had a 2-fold 
higher breast cancer risk than expected (95% CI, 2.1–15.2 and 1.1–3.6). 
Second to breast cancer, female genital malignancies contributed the most to the excess 
cancer risk observed with an AER of 9.7/ 10 000 person years (95% CI, 2.4–21.5). 
Subsequent CNS tumor- and skin cancer risk was only higher than expected among OS 
survivors (SIR 6.4; 95%CI, 3.2–11.4 and SIR 2.5; 95% CI, 1.3–4.3). Genitourinary 
malignancies contributed significantly to the excess risk if the primary bone sarcoma was 
located in the pelvis (AER 22.3; 95 CI, 1.5–72.7). The risk for digestive tract malignancies 
was not elevated for neither OS nor ES survivors compared with the general population (SIR 
overall 0.7; 95% CI, 0.3–1.5). 
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By specific SPN, the highest overall risk was observed for bone sarcoma and soft tissue 
sarcoma, which was nearly 14- respective 21-fold higher than for the general population 
(95% CI, 1.7–49.7 and 8.9–40.5 for bone and soft tissue sarcoma respectively). However, due 
to the low incidence rate in the general population, the absolute excess risk was only 1.1 and 
4.5 / 10 000 person-years for bone and soft tissue sarcoma respectively (95% CI, 0.1–4.2 and 
1.8–9.1). The highest SIR for soft tissue sarcoma was observed among ES survivors, who had 
a 67 times higher risk than that of the general population (95% CI, 21.9–157, AER 9.8; 95% 
CI 3.1–23.1).  
The risk for hematological malignancies were higher than expected among ES as well as OS 
survivors (SIR 5.5; 95% CI, 1.5–14.4 and SIR 1.6; 95% CI, 0.6–3.5). Hematological 
malignancies were together with CNS, the only malignancies that demonstrated the highest 
SIR within 5 years after diagnosis (SIR 6.1; 95% CI, 2.2–13.3 and SIR 6.3; 95% CI, 1.3–18.3 
for hematological and CNS respectively). 
The median time from OS or ES diagnosis to SPN was as follows; breast cancer; 24 years 
(range 1-49 years), soft tissue sarcoma; 18 years (range 1-44 years), skin cancer; 15 years 
(range 2-46 years), CNS tumors; 17 years (0-49 years), genitourinary malignancies; 22 years 
(0-48 years), female genital malignancies; 18 years (range 0-40 years), hematological 
malignancies; 5 years (range 0-31 years). 
4.3.1 Conclusion 
Ewing- and osteosarcoma survivors have elevated cancer risks compared with the general 
population attributed to specific cancer types. The risk in relation to the population remains 
elevated even past 30 years of follow-up. Female ES patients are at high risk for breast 
cancer, but the excess cancer risk was also driven in large by female genital malignancies, a 
finding that may indicate a role of BRCA-associated phenotype among a subset of patients. 
The increased risk for OS and ES patients was also high in recent treatment eras, indicating 
the need for prolonged surveillance among these patients, even with modern treatment 
regimes.   
4.4 THE ROLE OF LOCAL TREATMENT ON LOCAL FAILURE AND LATE 
EFFECTS IN A PEDIATRIC EWING SARCOMA COHORT (STUDY IV) 
This study had two main aims; first we asked the same research questions regarding reasons 
for disease failure as posed in study I and II, albeit with a different cohort .Additionally, we 
included patients with ES not only confined to the spine and pelvis, but with any ES location 
(including head and neck ES). Secondarily, since we were totally lacking treatment variables 
in study III, we sought to investigate the effect of treatment on late effects such as 
hospitalization, SPNs and death unrelated to disease failure. 
Of the 229 patients in the cohort, we had complete treatment details on 205 patients. In this 
cohort, only18/205 (17%) patients were treated locally with radiotherapy alone. A 
surprisingly large percentage of patients (n=97) were treated exclusively with surgery (47%). 
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Patients treated with surgery alone had less often metastasis at diagnosis (10%) compared to 
patients treated with RT alone (32%) or surgery with RT (31%). Tumor size was similar 
across all treatment groups. Local failures were observed in 37(16%) of the patients. The 
local failure rate at 5 years was 28% for patients treated with RT alone and 11% for patients 
treated with surgery alone (P<0.05). The local recurrence-free survival rate was only 47% at 
20 years for patients treated with RT alone. 
Among surgically treated patients, 65% had a wide resection margin. Better local control was 
achieved if a wide surgical margin was obtained compared to a marginal one (the 5-year local 
recurrence-free survival rates were 90% and 69% for patients with wide and marginal 
margins respectively (p<0.05). 
Nevertheless, there was no difference in local recurrence-free survival rate among patients 
who had a wide margin and patients with a marginal margin who also received RT (p=0.27) 
(Fig 7). For patients with a marginal margin without RT, the 5 year local recurrence-free 
survival rate was only 58% compared to 91% for patients with a wide surgical margin 
(p=0.02) (Fig 8). 
Adding RT to patients with a wide surgical margin did not improve the local control rate 
(p=0.33) (Fig 9). Moreover, there was no difference in local control rate for patients with 




Fig 7 Five year local recurrence-free survival rates of 91%, 79% and 82% for patients with 







Fig 8 Five year local recurrence-free survival rates of 91%, 58% and 86% for patients with 
wide margin-no RT, marginal margin-no RT and intralesional margin-no RT respectively 





Fig 9 Five year local recurrence-free survival rates of 87% and 91% for patients with wide 





Fig 10 Five year local recurrence-free survival rates of 83% and 86% for patients with 
intralesional margin with RT and intralesional margin-no RT respectively (p=0.66). 
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The 10 year overall survival rate for patient was 23% and 66% for patients with and without a 
local relapse respectively (p<0.05). 
Eight subsequent primary neoplasms occurred in 7/229 individuals (Table 2). 
Table 2 Subsequent neoplasms  
Patient 
no 






 1 Acute myeloid leukemia 5 years Pelvis RT 
2 Parathyroid adenoma 25 years Rib Surgery 
3 Cervical intraepithelial 
neoplasia (CIN) 
6 years Femur RT 
4 Cervical intraepithelial 
neoplasia (CIN) 
7 years Rib Surgery 
5 Osteosarcoma  5 years Foot RT 
6 Bilateral breast 
malignancies 
32 years Unknown Surgery 
7 Cervical intraepithelial 
neoplasia (CIN) 
22 years Femur Surgery 
 
Of the 13 late deaths that occurred, only 2 were caused by other reasons than disease relapse. 
Forty out of 99 patients without relapse of disease were admitted to hospital after 5 years of 
follow-up. There was no difference in hospital admittance across type of local treatment (Fig 










Fig 11 Hospital admission (yes/no) not related to disease relapse after 5 years of follow-up. 
4.4.1 Conclusion 
This study supports aggressive local treatment with surgery striving for wide margins in order 
to achieve local control which is essential for improved survival. If only marginal margin is 
obtained, adjuvant RT should be given. This study could not prove any benefit of adding RT 
for patients with a wide or intralesional margin. Subsequent primary neoplasms were few and 
unrelated to local treatment. Late mortality unrelated to disease relapse was low. However, 
treatment related morbidity, assessed by investigating hospital admission after 5 years of 





Many cancer patients, particularly children, have seen the benefit of recent advances in 
systemic treatment as well as radiation and surgical treatment. Unfortunately, the standard of 
care has not changed notably in the last decades for patients diagnosed with Ewing sarcoma, 
where conventional chemotherapy and local treatment with surgery and/or radiotherapy is 
still the mainstay of treatment. Fusion-derived antigens and CD 99 or IGF1R expression are 
potential targets that could be approached by cancer vaccines or chimeric antigen receptor T-
cell therapy (CAR-T). Nevertheless, studies investigating the possible role of such treatments, 
as well as the use of immune checkpoint inhibitors have not been promising
42
. For patients 
with non-metastatic ES the prognosis with conventional treatment is good; however, for 
patients with metastatic disease overall survival is dismal. Important research questions 
which need to be answered are: which novel systemic treatment is most promising and should 
be included in future multinational trials for patients with metastatic disease or for poor 
responders to chemotherapy? What is the optimal combination and timing of current 
chemotherapy? What is the role of whole lung radiation for patients with lung metastasis? 
Which local treatment strategy, surgery, RT or the combination of both results in best local 
control and what are the late effects of clinical importance related to treatment modality? In 
the four studies presented in this thesis, we aimed to shed light on the latter question.  
Local treatment in ES is controversial
31,43-45
. Some studies have questioned the contribution 
of local failure to overall disease failure, while other studies highlight its importance
12,29,46,47
. 
In study I, II and IV which are based on 3 different cohorts, local control was pivotal for 
overall survival, with a 5 years overall survival rate between 20% and 30 % for patients with 
local failure.  
For a patient with metastatic disease at presentation, definitive RT may seem like the best 
local treatment option, but if the patient responds well to chemotherapy with remission of the 
metastatic disease, surgery may be the preferred treatment. Metastasis, tumor size and site, 
patient age, national and institutional practice and patient preference are all important factors 
affecting the choice of treatment but also disease relapse. Therefore, these factors must be 
accounted for in all studies on local treatment with regards to local and distant relapse.. 
In study 1, the clinical observation of a sacral tumor localization being a favorable prognostic 
factor was confirmed in terms of disease-free survival in a Scandinavian cohort. We adjusted 
for tumor size which was the most likely known confounder and still found sacral site to be 
an independent favorable prognostic factor. Tumor size is universally believed to be a 
negative prognostic factor, although many have questioned its relevance
4,27,31
. In contrary to 
what was seen for ES of the non-sacral pelvis and spine as well as for the whole cohort in 
study IV, local control using RT alone was excellent for ES of the sacrum. The favorable 
prognosis associated with sacral site is difficult to explain since there are no other studies to 
confirm or dispute this finding. Another observation that was puzzling was the high 
percentage of metastasis at diagnosis (41% compared with 38% in the innominate bone) 
found in the group of patients with sacral ES. This may indicate that inherent biologic factors 
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assigned to sacral site play a role in metastasis and response to treatment. A theory would be 
that the tumors of sacral site are supposedly well vascularized leading to early metastasis, 
perhaps by direct tumor ingrowth into the prominent vessels of the presacral venous plexus. If 
metastasis is driven by direct tumor seeding into the circulatory system instead of for instance 
hypoxia, which is a known underlying mechanism of metastasis, this could also explain the 
better response to chemotherapy. In other words, a sacral tumor may metastasize early but 
respond better to chemotherapy. The good local control in sacral ES using exclusively 
radiotherapy could also be interpreted in the same context; a well vascularized tumor may 
respond better to radiation treatment than for example a necrotic, poorly vascularized tumor 
of the ilium. The significance of necrosis in relation to survival has been well demonstrated in 
a paper from 1986 examining the histopathology of 286 untreated cases of ES
48
.  
This theory has clear limitations, for one there is no data to confirm the positive prognostic 
value of sacral site found in our study. Therefore, our findings must be validated in other 
cohorts. Secondly, there are no publications to support that the presence of necrosis or other 
differences in tumor microenvironment can be attributed to site. Indeed, some studies have 
shown that subsets of ES with specific genetic mutations affecting the p53, p16INK4, 
p14ARF and MDM2 genes are associated with poor response to chemotherapy and thereby 
poor prognosis
49-52
. Whether these findings can be related to site needs to be elucidated.  
Another limitation to this study which may play a significant role is the duration of follow-
up. We have seen in studies I, II and IV that recurrences may occur later than within the 
classical 5-year follow-up period, some recurrences can occur even as late as 10 years after 
diagnosis (Study II). Theoretically, definitive RT as performed in the majority of patients 
with sacral ES, may not prevent, but just delay the onset of local recurrences. Although the 
mean follow-up time in study I is 5.4 years (including patients dying due to disease), the 
duration of follow-up raises some concern since it may be too short to draw strong 
conclusions. It is therefore necessary reevaluate this cohort in the future to see if our findings 
stand true with extended follow-up.  
Local treatment was not statistically significant as a prognostic factor for overall survival, 
although 8 patients in the innominate bone group and none of the patients in the sacrum 
group had a relapse, but were still alive at the end of the study period. Therefore, it is likely 
that a difference in OS would be seen with a longer follow-up.  
There were not enough local recurrences for a meaningful analysis with regards to local 
treatment. Nonetheless, there was an indication (p=0.07) that local treatment affected disease-
free survival. This may indicate an underreporting of local recurrences or that distant relapse 
and death are competing events for local recurrences. Although, not significant in the overall 
survival analysis, local treatment is likely to be biased as patients with favorable disease 
characteristics are generally treated surgically.  
For patients that were treated surgically, we were not able to prove that margin was a 
prognostic factor for local or distal relapse in study I (in contrary to study IV). Although, 
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overall survival was significantly affected by surgical margin, we did not include surgical 
margin in the multivariate analysis, simply because we chose to include the covariate local 
recurrence, which also reflects patients treated without surgery. We chose to dichotomize 
surgical margin into R0 and R1 resections instead of into wide, marginal and intralesional. 
This was done because in many studies, R0 and R1 classification is the preferred way to 
describe a surgical margin, perhaps because separation between marginal and wide margin is 
difficult and inconsistent. Furthermore, the nomenclature clear (R0) and contaminated (R1) 
margin, is commonly used in clinical practice in many parts of the world. Having only a 
dichotomous (R0 and R1) variable for margin requires less participants to show an effect, but 
it is also problematic because a lot of the R0 margins were marginal and therefore received 
RT.  
The more detailed margin description of wide, marginal or intralesional was used to show the 
effect of administering RT to surgically treated patients without adequate surgical margins. 
This could only be demonstrated in the overall survival analysis were there was a significant 
benefit of adding RT to patients with intralesional or marginal resection status. Even this 
result must be interpreted with caution; why were patients with intralesional or marginal 
margins not treated with adjuvant RT? Perhaps they had disseminated disease and a poor 
prognosis which precluded local treatment. The number of patients was too low to adjust for 
metastasis at diagnosis. Nonetheless, in study IV we were able to show the importance of 
surgical margin on local control, which supports the findings in study I.    
 Because of the anatomic and structural similarities between the sacral vertebrae and the 
mobile spine vertebrae we anticipated that some of the factors usually subject to bias such as 
tumor size and choice of local treatment would be eliminated when comparing the two sites. 
This was the case for tumor size which was on average 8 cm for both sites. A slightly higher 
proportion of the ES located in the mobile spine were treated surgically (6/24) compared to 
the sacrum (5/29). Interestingly, all surgically treated patients in the mobile spine cohort were 
treated in one institution, none relapsed, and all patients were alive at end of follow-up. Two 
other studies, each with 6 surgically treated mobile spine ES, published results with 100% 
local control
53,54
. The comparison between the two sites is very limited by the lack of power 
making it unjustified to give the results any merit. It is also worth mentioning that local 
control in the mobile spine was not as good as in the sacrum. Overall survival for tumors of 
the mobile spine seemed to be intermediate compared with the innominate bone and the 
sacrum. The limited number of other studies comparing fixed and mobile spine ES have 
showed contradictory results
55-57
. Two studies with only 7 respective 13 sacral ES showed 
inferior disease-free survival for sacral site
58,59
. However, three other studies, two of which 
had smaller cohorts, and one larger than ours could not prove a difference with regards to 
site: disease-free survival at 5 years was between 35% and 45%
56,57
. The local recurrence rate 
found in study II was comparable to what has been presented by others
53,59-61
  
Even though the low numbers in the study limits analysis of primary treatment, it was worth 
noting that emergency decompression tended to negatively affect local control. This concern 
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has also been raised by others
55,61,62
. It is reasonable to assume that a laminectomy, which 
usually has to traverse through the tumor, increases the risk for local relapse. Even though 
most patients in our study presented with neurologic deficits in the present study, most 
recovered regardless of treatment mode. This may reflect the effect that chemotherapy 
usually has on ES, causing a volume reduction quite rapidly after start of induction treatment. 
However, even this needs wary interpretation. It is possible that the patients who underwent 
urgent decompression had more severe neurologic compromise than patients who did not 
undergo spinal decompression, and that the good results observed in this group would not 
have been as good if decompression had not been performed. It is possible that post-operative 
radiotherapy can compensate for the increased risk of performing urgent laminectomy, in 
which case the procedure is justified. Another point is that for a patient presenting with 
neurologic symptoms and a spinal tumor of unknown etiology, an emergency decompression 
will quickly give tissue for histopathology. At some centers, a frozen section can be done 
during surgery, thus allowing prompt diagnosis and start of systemic treatment.  
Also the risk for local relapse may be overestimated (or underestimated) as the number of 
recurrences (5 patients) was low making statistical analysis unreliable. 
The complications delineated among spinal ES patients in study I are predominantly surgical 
complications, some perhaps are worsened by the combination of surgery and radiotherapy. 
They are of interest, because some are avoidable. In particular, if an emergency 
decompressive procedure is performed without posterior stabilization, there is a risk that a 
sagittal deformity (usually gibbus) will occur in the spinal column. Therefore, authors have 
advocated that posterior stabilization should be performed
63
. Five gibbus deformities 
developed in our cohort, some of which would have been avoided with posterior stabilization. 
The downside of posterior stabilization, which is usually done by the use of titanium rods and 
screws, is that the surgical wound becomes bigger necessitating a larger field of post-
operative radiotherapy. The risk for surgical site infection increases manifold, a complication 
that may delay chemotherapy. Also, the presence of hardware in the spine impedes the use of 
magnetic resonance imaging (MRI) to surveil the surgical site for local recurrences. The less 
sensitive computer tomography (CT) can be used, but even this modality is troubled by 
hardware. Good artefact reducing software have reached the market but monitoring for local 
relapses is still by far easier in a patient without spinal hardware. Moreover, titanium or 
stainless-steel rods and screws are not compatible with the use of emerging radiation 
techniques such as proton- or carbon ion therapy. Another point that should discourage spinal 
stabilization is that many patients will not live long enough to develop spinal deformities.  
Indeed, most patients that underwent posterior decompression without posterior stabilization 
did not develop a spinal deformity. Posterior stabilization in this group of patients would be 
overtreatment.  
The risk of treatment-related secondary malignancies is a variable that is attracting increased 
interest in the decision-making regarding the use of radiotherapy, one reason being that 
before the era of multi agent chemotherapy many of these patients never survived long 
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enough for the secondary malignancies to occur. Now that more childhood and young 
adulthood cancer patients survive and are starting to reach an age in which cancer is more 
common in the general population, we are observing an increasing number of secondary 
cancers. Although secondary cancer is seen after treatment of all childhood malignancy, 
lymphoma and ES survivors belong to the group of patients which have shown the highest 
risks
40
. Subsequent malignancies after treatment of cancers occurring mainly in adults are 
also a concern, but the age distribution in adult cancer makes the risk in adults less of an 
issue. Some subsequent tumors can be a serious concern even though they are not malignant, 
an example being benign brain tumors such as meningioma, which are commonly registered 
in cancer registries. Subsequent primary neoplasm (SPN) is therefore a term frequently used 
when reporting on secondary neoplasms, as it encompasses the few benign tumors that may 
have more of a malignant course. 
 Genetic factors as well as treatment related factors such as chemotherapy and radiotherapy 
are all associated with the risk of developing SPNs among bone sarcoma survivors
64-66
. The 
genetic factors associated with a general increased cancer risk are concentrated to 
osteosarcoma patients. No known inheritable factors are coupled to the increased risk seen in 
ES. The chemotherapeutic agents used in treatment of ES and OS, particularly alkylating 
agents, but also anthracyclines are known to be carcinogenic, increasing the risk for mainly 
for hematological malignancies but also for solid tumors such as breast cancer and OS
67-71
. 
Even treatment with platinum-based agents, which is used in treatment of OS, increases the 
risk for secondary malignancies
72
. Radiotherapy, is the only modifiable risk factor
9,40,73
.  
The literature search performed ahead of study III showed a wide range in risk estimations 
calculated for SPN among ES patients. The studies which were uncontrolled and not 
population based, showed cumulative incidence rates varying from 5% at 10 years to 35% at 
10 years 
74-79
. There are two well-documented large pediatric cohorts, the North American 
Childhood Cancer Survivor Study (CCSS) and the British Childhood Cancer Survivor Study 
(BCCSS), both of which have yielded numerous studies on the risk for SPN among childhood 
cancer survivors.
73,80
. The cumulative incidences of SPN among ES survivors in these cohorts 
were 9% and 10 % at 30 years, which correlates strikingly well with the results in study III 
(9% at 30 years). The BCCSS and CCSS are pivotal studies due to the size, extensive 
longitudinal follow up and detailed treatment information. Both studies have their limitations: 
treatment details were by no means complete (75% and 83% completeness respectively) and 
one third of all eligible patients in the CCSS cohort were lost to follow-up or refused to 
participate. Furthermore, the study period for the BCCSS cohort was only up to 1991, and in 
the CCSS cohort up to 1999, thus the results do not reflect the current trends which may have 
changed substantially. Lastly, the BCCSS cohort only included patients younger than 15 
years of age. However, these studies raise two important questions which have been 
addressed in study III: for how long does the risk remain elevated compared to the general 
population, and what are the risks for patients treated after 1991 and 1999 respectively? The 
BCCSS claimed that the risk for SPN among bone cancer survivors was no higher than for 
the general population after 30 years of follow-up. The study also assigned a significant cause 
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of the excess cancer risk to bone sarcoma, even more than to breast cancer. In study III we 
saw a tendency for a decline in risk over time, which nonetheless remained elevated past 30 
years of follow-up. This was mainly driven by the excess breast cancer risk among ES 
survivors. In contrary to the BCCSS results, we also found that excess risk due to secondary 
bone cancer among ES and OS survivors constituted a rather small proportion. A likely cause 
for the contradictory results found in the BCCSS cohort and in study III is the low number of 
observed and expected cases in the BCCSS cohort. In the latter only 5 SPNs were reported 
past 30 years of follow-up, compared to the 21 cases observed in study III. Two of the 5 cases 
of SPN in the BCCSS cohort were breast cancer and none were due to bone sarcoma. In the 
whole BCCSS cohort there were 13 subsequent bone sarcomas, thus more than observed in 
study III. It is therefore reasonable to believe that with longer follow-up and more survivors 
entering the +30 years of follow-up group, we would see more SPNs, as observed in study 
III. The differences observed in risk attributed to subsequent bone sarcoma among primary 
OS and ES patients may be due to two reasons; either the BCCSS cohort, basically reflecting 
the whole of Great Britain, has been subject to more extensive radiotherapy than the Swedish 
cohort, or the interpretation of what is a subsequent bone sarcoma differs between the studies. 
The latter does represent a difficult issue and may be the cause of differences seen in other 
cohorts; how do you know that a subsequently occurring bone lesion (-s) with a morphology 
consistent with OS is de facto a synchronous or metachronous OS and not a bone metastasis 
of the same clonal origin as the initial bone sarcoma? Even if the subsequent OS is clonally 
different, let’s say with a histopathology in line with an undifferentiated pleomorphic 
sarcoma of bone, the lesion can be a metastasis that has dedifferentiated from the original OS 
rather than a radiation-related new bone sarcoma. The problem is only relevant among OS 
survivors, because the morphology of a subsequent bone sarcoma in an ES survivor is so 
different from the morphology in the primary ES that it simply cannot have derived from the 
original ES. Although unlikely, there may be situations of subsequent ES occurring long after 
the primary ES where the same problem occurs, and that the subsequently occurring ES is 
wrongly recorded as a SPN. For the situations in study III where the morphology codes of the 
original bone sarcoma were the same as the subsequently occurring bone sarcoma, the 
subsequently reported bone sarcoma was not recorded. It is not clear how they have handled 
this issue in the BCCSS study or most other studies, but it may reflect why the subsequent 
bone sarcoma risks are lower in study III than in many other studies
80-83
.  The authors in the 
BCCSS discuss why lower SPN risk was observed after 25 years of follow-up and conclude 
that the excess risk among bone sarcoma survivors is caused by direct radiotherapy exposure, 
and with extended follow-up survivors reach an age in which other subsequent malignancies 
than bone sarcoma dominate, such as breast, digestive tract, genitourinary and lung 
carcinomas. These malignancies are according to the authors unlikely to be higher than 
expected among primary bone sarcoma survivors, for which an estimated 80% of the patients 
had a primary bone sarcoma in the limbs, accordingly unlikely to have received radiotherapy 
to the sites in which these malignancies arise. There are two main oppositions to this 
explanation; only 70% of ES in their cohort were located in the extremities. In study III, 43% 
of ES and 15% of OS developed in a central location, in which the malignancies discussed 
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above arise. In other studies 1/3 to 1/2 of ES are located in the axial skeleton
84-86
. 
Furthermore, tumors arising in the scapula are coded as an extremity location according to the 
WHO- ICD classification. ES patients with a primary tumor located in the scapula, or even in 
the proximal upper arm, may therefore well have received RT towards the breast tissue.  
Another observation from study III was that the overall standardized incidence rates (SIRs) 
for SPNs among ES and OS survivors were in the lower range compared to the BCCSS and 
some other studies. Absolute excess risks (AERs) on the other hand, were in the higher 
range
80,82
. It is reasonable to believe that this is due to the BCCSS and other cohorts being 
younger, as SIRs in the lower age group in study III also had higher SIRs. The difference in 
AERs may reflect a higher background cancer incidence in the Swedish population. If the 
aim is to reduce the number of survivors developing SPNs, then the focus should be on breast 
and female genital malignancies, because the highest AERs were seen for these malignancies.   
In study III we saw an increased risk for SPNs even in the latest treatment era (2000-2015) 
however; it was insignificantly lower than for the previous (1980-1999) time period. If this 
was more than a decreasing trend, did it reflect more restricted use of radiotherapy or perhaps 
that modern radiotherapy techniques are less likely to cause secondary malignancies? A 
lower risk could hardly be assigned to changes in chemotherapy as standard treatment has 
remained constant across the previous treatment eras. In North America, we know the use of 
radiotherapy for patients with childhood malignancies has been reduced, even so for ES 
patients
73,87
. The latest CCSS report showed a lower overall cumulative incidence for 
subsequent malignant neoplasms among patients treated the latest (1990-1999) study period, 
a phenomenon assigned to changes in the use of radiotherapy. In the subgroup analysis, no 
decrease was seen for OS or ES survivors, which by all means could be a result of 
insufficient power. Anyway, temporal trends will often misinterpret changes in the latest time 
eras simply because the follow-up time is shorter. As follow-up time increases so will the 
number of patients developing SPNs. It is therefore likely that we will continue to see an 
increasing number of SPNs among bone sarcoma survivors in the future. 
The lack of treatment details is the major limitation in study III. It was one of the reasons that 
OS patients were included as a comparative group. Chemotherapy-related differences 
between ES and OS are small and do not need to be accounted for, but as a proportion of OS 
patients will harbor genetic changes predisposing for subsequent malignancies, higher risks 
could be foreseen in this group.  We did not exclude patients with hereditary retinoblastoma, 
who have a known high risk for OS, still ES showed double the risk compared to OS. Hence, 
a large part of the excess cancer risk in ES must be attributed to RT.  Moreover, we found 
higher risks for centrally (axial skeleton) located tumors, a risk that was attributed to female 
genital malignancies, and urogenital malignancies. The risk for subsequent breast cancer was 
only elevated for centrally, but not pelvic primary bone tumors. These are sites in which 
surgery with wide margins is very challenging, and most survivors will have received RT. 
These findings point towards RT being a significant contributor to the excess risk for ES 
patients. Overall, OS and ES survivors did not show an elevated risk for digestive tract 
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malignancies in study III. This is perhaps somewhat unexpected. The bowels are likely to 
have been exposed to radiotherapy in ES survivors with tumors in the pelvis and lower spine. 
The BCCSS group found a high AER for colorectal cancer among childhood survivors who 
had reached the age of 40 and undergone direct abdominopelvic radiation
88
. The risk was 
literally comparable to that of individuals with a genetic predisposition to colorectal cancer, a 
patient group in which screening with colonoscopy is recommended. Regarding specific 
childhood malignancies, the study presented the risks for bone sarcoma as one entity, for 
which the risk was not significantly elevated. Once again, the results must not be over 
interpreted and could be a result of low numbers. In study III we did actually see an increase 
in digestive tract malignancies for ES survivors, although insignificant and concealed in the 
overall analysis by OS survivors who showed a lower risk. Even in the BCCSS, there was an 
insignificantly higher risk among bone sarcoma survivors that might increase further as more 
patients reach the age in which this cancer type is more common. However, we can conclude 
that digestive tract malignancies did not constitute a major contributor to the excess cancer 
risk observed in study III or in the BCCSS.  
The pattern of SPNs also indicates that there are different etiologies driving the excess cancer 
risk for OS and ES survivors. ES survivors displayed an elevated risk for the development of 
all solid tumors except for CNS and skin cancer. OS survivors on the other hand did not show 
elevated risks for genitourinary and digestive tract malignancies, but the risk was elevated for 
other solid tumors. One could expect that the skin cancer risk would be elevated among ES 
survivors if RT was a main risk contributor, otherwise the risk for solid tumors according to 
these findings indicates that RT plays a major role among ES survivors, while a genetic 
susceptibility dominates the enhanced risk observed among OS patients. The hematologic 
malignancies, which were elevated among OS and ES survivors, tended to occur early in the 
follow-up period, and were most likely caused by the chemotherapeutic agents that are used 
in treatment of both ES and OS. Indeed, ES patients appeared to be at a higher risk for 
hematologic malignancies than OS patients. 
The significant contribution of female genital malignancies to the excess cancer risk observed 
among ES and OS survivors is a novel finding that needs to be confirmed. Together with 
breast sarcoma, we found the two malignancies contributing to nearly 60% of all absolute 
excess risk among ES survivors. Germline mutations in the BRCA1 or BRCA2 genes are 
typically seen among subsets of breast and ovarian cancer patients; however, tumor mutations 
in BRCA pathways are seen in a variety of other malignancies. Our finding raised the theory 
of a BRCA like phenotype existing among a subset of ES or OS patients. The literature 
investigating BRCA traits among bone sarcoma survivors was nonetheless scarce
89,90
.  
The absolute excess risk for cancer seen among bone sarcoma survivors is relatively small 
and deserves to be put into critical perspective. Even though the risk for a subsequent 
sarcoma (bone or soft tissue) to occur in a patient surviving ES is 115 time that of the general 
population, the AER is actually just14 extra sarcomas / 10 000 person years. On the contrary, 
due to the high cancer rate in the adult general population, the excess risk for breast cancer 
 
38 
among ES survivors followed past 30 years after diagnosis amounts to nearly 130 / 10 000 
years.  
ES and OS survivors are not only at risk for secondary cancers, but also for a wide range of 
other serious medical conditions
91
. Much work is therefore being done into systematically 
following these children and young adults long after they have reached the adult world and 
are considered cured from their primary cancer. Surveilling for secondary cancers is one such 
important measure included in long-term follow-up clinics / late effect-clinics. In Sweden, 
such clinics are satisfactorily evolving, owing to the work done by the six regional cancer 
centers (RCC) in collaboration with the Swedish working group for follow-up after pediatric 
cancer (SALUB). There are existing guidelines for caregivers, not only working in the field 
of oncology, which is important as treatment-related morbidity involves a broad range of 
organs. Evidence for screening after childhood cancer is perhaps best described for survivors 




The aims in study IV were based on the results of study I, II and III. The lack of treatment 
data in study III warranted a new study with a cohort where detailed treatment information 
was available. Morbidity and treatment-related mortality were also of interest as these 
parameters were lacking in study III. Initially, the idea was to classify all complications into 
surgical, radiation-related or as a result of chemotherapy. However, it proved very difficult to 
ascertain which complication or type of reoperation was related to which treatment. Many 
times, it was a combination of different treatments. Therefore, we decided to use late hospital 
admittance/hospital stay as an indicator of morbidity. Cause of mortality was also recorded so 
that mortality due to subsequently occurring cancers or other serious side-effects such as 
heart failure would reflect the severity of treatment-related complications.  
Also, due to the relatively low numbers in study I and II, another aim in study IV was to 
evaluate whether choice of local treatment and surgical margin had an effect on local failure. 
Local failure is a better outcome in evaluating local treatment than disease-free survival or 
overall survival, but it requires a larger cohort due to the relatively low local failure rates, 
which varied from 5% to 20% in study I and II. The Swedish child cancer registry satisfied 
those criteria since it encompassed good data on treatment and follow-up.  
One of the main findings in study IV, that radiotherapy improves local control in patients 
with marginal resection status, was a confirmation of what was anticipated in study I. In study 
I, the beneficial role of surgery + RT was only demonstrated in the overall-survival analysis. 
One could argue that this could be a result of selection bias. Depicting the same positive 
effect of RT in a local recurrence analysis, which is far less likely to be a result of selection 
bias, confirms the importance of RT in marginally resected tumors. Also concluded from 
study IV; local control was not improved by adding radiation treatment to patients with a 
wide margin. The same observation was made in study I, although only in the overall survival 
analysis. Why patients with an intralesional margin did not benefit from RT is speculative; 
patients with intralesional margin had poorer overall survival than patients with wide margin. 
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They also had more distant relapses than patients with marginal margin. Perhaps, patients 
with intralesional margin after surgery had fewer local recurrences due to death as a 
competing risk. Moreover, there may be an underreporting of local relapses among patients 
suffering synchronous distant and local relapses.  Even though there are difficulties 
associated with defining a marginal respective wide or even intralesional margin, study I and 
IV clearly show the benefit of discriminating marginal from wide margins as compared with 
an R0/R1 description. 
Even though most would advocate surgical treatment over RT, there is still a question to 
whether definitive RT is inferior to surgery in achieving local control
29,32,93-96
. In one of the 
cooperative Ewing sarcoma studies (CESS), a better local control was seen for surgically 
treated patients compared with patients treated with definitive RT, but no difference was seen 
in distant relapse, thereby questioning the significance of local control
97
. A very interesting 
report was made on the EICESS randomized trial undertaken as a collaborative approach by 
the German Paediatric Oncology and Haematology Group (GPOH) and the Children’s 
Cancer Leukemia Group (CCLG) of UK. The aim was to investigate chemotherapy options 
for ES. They found an over 60% survival for the entire group at 5 years, but this concealed 
a14% inferior survival rate for patients in the CCLG cohort. Given the baseline 
characteristics and systemic treatment were the same, this was peculiar. The analysis revealed 
that the difference in overall survival was attributed to an inferior local control in the British 
cohort where local treatment was clearly less aggressive. The CPOH cohort was more often 
(66% vs 24%) treated with combined modalities (surgery+RT) and less often with definitive 
RT. GPOH patients also received local therapy earlier; 43% and  9% in the GPOH and the 
CCLG group respectively, received local treatment (generally pre-operative RT) within 12 
weeks after start of induction chemotherapy
46
.   
The results from study I, II and IV support the importance of achieving local control. Sacral 
ES excluded; study I showed a strong trend for a better disease-free survival for surgery or 
surgery+RT compared with RT alone. In study IV, better local control was achieved with 
surgery or combination treatment than with definitive RT. The key message from these 
studies and the latter EICESS study is that local control is pivotal, and aggressive local 
treatment, with combined surgery and RT if a wide margin is not achieved, is essential for 
survival. 
There were few late deaths (only two) in study IV due to other reasons than relapse of the 
primary disease.  The conclusion drawn from this study is that much longer follow-up is 
needed to assess mortality related to primary treatment. Another point made is that disease 
relapse is the major cause of mortality for much longer than 5 years after diagnosis. 
Therefore, a larger cohort with more patients surviving past at least 20 years of follow-up is 
required to investigate mortality caused by treatment.  
The same conclusion applies to the analysis of secondary malignancies in relation to local 
treatment. Typical treatment associated SPNs, such as an acute leukemia and a radiation-
related osteosarcoma, developed 5 years after diagnosis. Nonetheless, a much longer follow-
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up, or a larger cohort would have been necessary to assess the treatment related risk for 
SPNs. 
Almost half of the patients surviving past 5 years, and without a disease relapse, were 
admitted to hospital and hospitalized for a median of almost 9 days. There seemed to be an 
over representation of surgically treated patients subject to late (+ 5 years) admission to 
hospital, but this was not significant. Charts were reviewed to investigate the cause of 
admission, but the causes varied significantly regarding severity and type ranging from 
reconstruction of surgical scars to organ transplantation. Typical causes were deformity 
surgery due to leg length discrepancies, amputations, neurologic sequelae, pathological 
fractures, late infections after surgery, renal and cardiac failures etc. As stated earlier, 
categorizing complications in relation to treatment is challenging because there is no clear 
definition of what is regarded as a serious complication and what is a more expected reason 
for admission, for example revision of implant due to mechanical wear. The study showed 
that many patients were admitted to the hospital long after end of treatment, but worth noting 
was that the majority were not admitted to hospital after the first 5 years of follow-up. 
Hospital admission was also studied by the BCCSS group which showed that bone sarcoma 
survivors were twice as likely as the general population to be hospitalized as an inpatient than 
the general population. No difference in the need for late hospitalization was seen between 
OS and ES patients
80
. 
6 FUTURE PERSPECTIVES  
One lesson learned during the work in this thesis, obvious to the epidemiologist, is that it is 
important to have a good research question, but without enough power to detect a difference, 
the question cannot be answered. A struggle with power was obvious throughout most of the 
studies in this thesis. However, the author was in good company as lack of power was evident 
across most scientific literature on the topics of this thesis. Therefore, results drawn in many 
studies were often uncontrolled or made upon biased comparisons, subject to type I and II 
errors or over-interpretation of the effect of a certain exposure. Another phenomenon, 
commonly observed in large scale studies on childhood cancer survivors, was that OS and ES 
patients were pooled together and presented as “bone sarcoma”. This thesis and other studies 
show that OS and ES are two very different entities with different inherent risks and risk 
patterns for secondary malignancies. The cost of presenting the two different bone tumors as 
one entity in order to gain power is that key results may be concealed.  
Given the rare nature of the disease, it would have been beneficial if the author would have 
used the available registries in all of the Nordic countries. Good registries with similar 
variables exist throughout our countries, and a collaborative effort would have yielded a 
better result.  
It´s clear that a significant number of bone sarcoma survivors face serious long-term 
complications. An ensuing goal would be to continue the work started in study IV; to identify 
the modifiable treatment related late-affects. Furthermore, retrospective and prospective 
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studies investigating patient related outcomes and functional outcomes in relation to local 
treatment should be within reach. In the Nordic countries, where population-based registries 
are similar and well administered, it should be feasible to agree on a way of recording and 
classifying complications and late-affects so that they can be properly addressed. Much good 
work has already been done through SALUB, which administer a registry recording late 
complications after treatment for childhood cancer. The Adult Life after Childhood Cancer in 
Scandinavia study (ALiCCS) is another promising large-scale collaborative study that will 
give important information on late effects.  Collaborating with these research groups would 
be a natural next step for the author.  
There is much work yet to be done in delineating the risks associated with administering 
radiotherapy and chemotherapy for ES. A next study would preferably be a case control 
study, in which patients with SPNs in the Nordic countries would be analyzed through 
national registries and compared with primary ES and OS patients not developing SPNs. 
Exposures at interest would be RT and chemotherapy. The same could be done for other 
complications examining surgery as an exposure.  
A low hanging fruit would be to investigate the role of early or pre-operatively administered 
RT. It is an approach that has been advocated in the Nordic countries and never been 
evaluated. The results from the GPOH cohort show that the early RT treatment approach may 
be beneficial with regards to local control. 
However, retrospective studies on local control and late effects related to traditional photon or 
electron RT may have less relevance in the future as emerging treatments such as proton or 
carbon ion treatment are being used more often in the treatment of ES. Such treatments 
should be considered in the coming clinical multinational trials. 
Another future perspective would be to include translational research into epidemiological 
studies. If tissue samples would have been available for study I, a difference in survival with 
regards to site could have been investigated simultaneously on a basic biology level. The 
same applies for the theory about BRCA like traits existing in OS and ES patients raised in 
study III. Consequently, the lesson learned is that the work up prior to starting a study is 
essential and significant effort should be done to engage basic scientists early so that the 
clinical data can be used on a molecular level. To promote translational research for a 
common disease, like for example breast cancer, is perhaps less of a problem as most basic 
researchers have access to tumor tissue. The lack of improvements in outcome over the last 
30 years for ES emphasizes the need to share tissue and clinical data for this rare disease.   
Perhaps reaching out to potential partners working with other rare cancers would be a way to 
achieve results faster. It may solve many problems concerned with funding, regulatory bodies 
and with the industry. It may also enable ES patients to participate in studies which are not 
restricted to specific cancer types. The INFORM study is one such registry-based study 
where tumor tissue is harvested aiming to offer individualized treatment for children with 
recurrent disease regardless of primary type of malignancy. 
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The author would also like to see an accentuated focus on local treatment when planning for 
multinational clinical trials. Much attention in pan European studies like Euro Ewing has 
been exclusively on the timing and combination of different chemotherapy regimens. 
Questions regarding local treatment have been completely lacking and assigned to the 
individual treatment centers. An increased engagement by sarcoma surgeons in these clinical 
trials is longed for. 
Low accrual in the multinational studies that have been undertaken in Europe is also a 
problem. This was evident in the Euro Ewing 2012 trial which closed in May 2019. It is also 
evident in the rEECur study conducted by the Euro Ewing consortium. The study 
investigating 4 different treatment arms (bio specimens are collected) for recurrent ES, was 
started in 2015 and has only accrued half of the 525 patients needed and until recently no 
patients from the authors’ institution. The study has wide inclusion criteria and almost every 
patient with a recurrent ES in the country should be given the opportunity to participate. To 
improve accrual, national sarcoma centers, or even better Nordic collaborations like 
Scandinavian Sarcoma Group, should take a leading role. Low accrual in clinical trials is a 
waste of human and economic resources and most importantly it leads to a failure in 
improving clinical practice. Fortunately, there are hopes on the horizon. Initiatives to promote 
clinical research, as currently being done by the EU funded studies of the Euro Ewing 
consortium, are admirable and will answer important research questions. 
7 CONCLUSIONS 
Based on the papers in this thesis, the following conclusions can be drawn: 
 Ewing sarcoma should be treated surgically if possible, if wide margins is not 
achieved, the addition of radiotherapy is crucial for local control.  
 Administering radiotherapy in the setting of a wide surgical margin for Ewing 
sarcoma is not indicated, the role of radiotherapy for intralesionally resected tumors 
is unknown. 
 Sacral site seems to be favorable prognostic factor compared with other pelvic sites.  
 Good local control of sacrally located Ewing sarcoma may be achieved with 
definitive radiotherapy. 
 Ewing sarcoma of the mobile spine is associated with a high local failure rate and 
surgery should be the preferred treatment of choice even in this difficult anatomic 
location. 
 The high local failure rate may be related to less aggressive  treatment (definitive RT) 
or to emergency decompressive surgery being performed in an emergency setting. 
 Neurologic recovery is excellent for the vast majority of patients presenting with 
neurologic symptoms, perhaps owing to the prompt response to chemotherapy more 
than to spinal decompression. 
 The excess risk for subsequent primary neoplasms  among osteosarcoma and Ewing 
sarcoma survivors has different etiologies and is driven by different cancer types 
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although breast cancer and female genital malignancies are the main drivers of 
excess risk for osteosarcoma as well as Ewing sarcoma survivors. 
 The cancer risk remains elevated compared with the general population past 30 years 
of follow-up and for patients treated in the latest treatment era. This indicates the 
need for prolonged cancer surveillence in this patient group 
 The risk for SPNs in Ewing sarcoma survivors are moderately elavated and should 




8 SAMMANFATTNING PÅ SVENSKA 
Ewing sarkom (ES) är en sällsynt och aggressiv malign tumör som drabbar främst barn och 
unga vuxna. Sjukdomen drabbar årligen ca 2.9 per million barn. Ewing sarkom är i 
pediatriska populationer det näst vanligaste skelettsarkomet efter osteosarkom och utgör 
tillsammans med osteosarkom 5% av alla maligniteter hos barn och ungdomar
8,14
. 
Multimodal behandling med kombinationscytostatika, kirurgi och strålbehandling är 
avgörande för prognosen. Överlevnaden över 5 år har dock stagnerat på mellan 60% och 70% 
sedan 30 år tillbaka
12,26,39,98-100
. Stora multinationella studier i syfte att optimera den bästa 
kombinationen och timingen av cytostatika har varit en besvikelse och har inte förbättrat 
överlevnaden för den 1/5 av patienterna som presenterar med metastatisk sjukdom
14
. Det 
ligger därför stora utmaningar i att förbättra den systemiska behandlingen av ES.  
Denna avhandling handlar dock om lokalbehandling av Ewing sarkom och den har två delar. 
Den första delen handlar om lokal behandling och lokal tumörkontroll i förhållande till 
kirurgisk marginal och anatomisk lokalisation. Den andra delen handlar om sena 
komplikationer hos långtidsöverlevare och främst risken att drabbas av sekundära 
maligniteter. 
Lokal behandling utgör närmast alltid ett diskussionsämne på multidisciplinära 
sarkomkonferenser. Orsaken är att många tumörer (35% till 45%) uppstår i eller i anslutning 
till axiala skelettet, dvs anatomiska områden som ligger centralt. Ur en kirurgisk synvinkel, är 
lokalisationen problematisk då kirurgisk excision med sedvanliga krav på kirurgisk marginal 
skulle leda till betydande funktionsnedsättningar. Strålbehandling, vilket historiskt sett haft en 
viktig roll i behandlingen av ES, är också behäftad med svårigheter när tumören är 
lokaliserad till axiala skelettet. Det kan vara svårt att komma upp i terapeutisk stråldos, och 
att uppnå önskat strålfält på grund av tumörens närhet till vitala strukturer. 
Strålbehandlingens negativa effekter på skelettet utgör också ett signifikant problem då den 
kan leda till betydande tillväxtstörningar och strålrelaterade frakturer. Dessutom utgör den 
ökade risken för strålrelaterade sekundära maligniteter ett uttalat bekymmer som allt mer 
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framkommer i diskussion. Kontrovers föreligger dessutom avseende hur stor betydelse valet 
av lokalbehandling har för lokal tumörkontroll och för överlevnaden. 
Målet med de fyra arbetena var att studera följande: vilken lokalbehandling som ger bäst 
lokal tumörkontroll för ES lokaliserad till bäckenet (arbete I); hur stor del av patienter med 
ES i kotpelaren som har neurologiska symptom vid diagnos, och vilken betydelse 
neurologiska symptom har för lokal tumörkontroll (arbete II); vad risken är för sekundära 
maligniteter (SPN) bland överlevare efter behandling för ES och OS, och vilken typ av 
malignitet driver riskökningen (arbete III); vilken betydelse kirurgisk marginal har för lokal 
tumörkontroll och vilken betydelse lokalt återfall har för överlevnad (arbete I och IV). 
ES utgående från sakrum är särskilt utmanande. I arbete I studerades en kohort bestående av 
117 patienter med bäcken ES, Där kunde vi visa att sakrala ES till stor del behandlas med 
enbart strålbehandling (definitiv strålbehandling) med goda resultat mätt i lokal 
tumörkontroll, sjukdomsfri överlevnad och total överlevnad. Vi noterade att sakral 
lokalisation i bäckenskelettet var en oberoende prognostiskt gynnsam faktor jämfört med 
övriga bäckenben (os ilium, os ischium och os pubis). Sakral lokalisation var förknippad med 
bättre sjukdomsfri överlevnad trots att en hög andel (41%) av patienterna med sakrala ES 
hade metastaser vid diagnos. Kirurgisk behandling tenderade dock att ge en bättre 
sjukdomsfri överlevnad för patienter med tumörer som inte var lokaliserad till sakrum. 
Slutligen kunde vi påvisa att postoperativ strålbehandling ledde till signifikant bättre 
överlevnad vid kirurgi med marginell eller intralesionell kirurgisk marginal. 
Sakrum är en del av kotpelaren och har följaktligen fler anatomiska likheter med övriga 
kotpelaren än med bäckenbenen. I arbete II undersöktes huruvida ES lokaliserad till 
kotpelaren hade motsvarande god prognos som observerats för ES i sakrum i arbete I. Vi 
undersökte också förekomsten av neurologiska symptom vid diagnos, hur de neurologiska 
symptomen behandlades och vilken effekt behandlingen hade på lokalt återfall. Studien som 
utgjordes av 24 patienter med tumörer i kotpelaren, visade att denna patientgrupp hade en 
relativt god prognos med en sjukdomsfri överlevnad i mellanskiktet jämfört med patienter 
med ES lokaliserad till sakrum och övriga bäckenet. Dock noterades en hög frekvens av 
lokala recidiv bland patienterna, vilka till stor del behandlades med definitiv strålbehandling 
framför kirurgi. Många patienter hade neurologiska symptom vid diagnos och genomgick 
därför akut dekompression av ryggmärgen/nervrötter innan diagnos. De allra flesta 
patienterna återhämtade sig dock neurologiskt oberoende av huruvida de genomgick akut 
dekompression eller inte. Akut dekompression tenderade att vara kopplat till högre risk för 
lokalt återfall. Lägre risk för lokalt återfall kunde kopplas till den senaste behandlingseran, 
vilket kan indikera att förbättrad systemisk behandling var orsaken till förbättrad lokal 
kontroll. 
Arbete III genomfördes för att undersöka risken för sekundära maligniteter bland överlevare 
efter behandling för Ewing- och osteosarkom i en nationell populationsbaserad kohort. 
Studien, som baserades på 1779 OS och ES patienter, visade att risken för sekundära 
maligniteter var dubbel så hög för ES- som för OS- patienter och 4 gånger högre än för 
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normalbefolkningen. ES och OS överlevare drabbades av olika typer av sekundära 
maligniteter, men för båda grupperna drevs riskökningen till stor del av bröstcancer och 
gynekologiska maligniteter. Kombinationen av den höga riskökningen för bröstcancer och 
gynekologiska maligniteter kan indikera att BRCA liknande fenotyper förekommer hos en 
del av patienter med skelettsarkom. Den ökade cancerrisken kvarstår efter 30 års uppföljning 
samt även för patienter som behandlats under den senaste behandlingseran.  
I arbete IV undersöktes en populationsbaserad pediatrisk ES kohort bestående av 229 
patienter ur Svenska Barncancerregistret. Kirurgi, kirurgisk marginal och strålbehandling 
utvärderades i förhållande till lokal tumörkontroll. Vi studerade även lokalbehandlingens sena 
effekter på sekundära maligniteter och behov av slutenvård. Kirurgisk excision gav betydligt 
bättre lokal kontroll och var associerad med bättre överlevnad än enbart strålbehandling. Bäst 
lokalkontroll observerades vid kirurgisk excision med vida marginaler. Strålbehandling 
förbättrade inte lokal kontroll vid kirurgi med vida marginaler. Strålbehandling spelade dock 
en viktig roll för att åstadkomma lokal tumörkontroll vid kirurgi med marginell marginal. 
Sena, icke återfalls relaterade komplikationer vilka resulterade i sjukhusinläggning efter 5 års 
uppföljning, var ungefär lika vanligt förekommande oavsett typ av lokalbehandling.  
Sammanfattningsvis utgör anatomisk lokalisation en viktig prognostisk faktor för patienter 
med Ewing sarkom. Kirurgisk marginal med vida marginaler ger i regel överlägsen lokal 
tumörkontroll jämfört med definitiv strålbehandling. Adjuvant strålbehandling i samband 
med kirurgi med marginell marginal ger dock lika god lokal tumörkontroll. Definitiv 
strålbehandling förefaller ge adekvat lokal tumörkontroll enbart vid ES i sakrum.  
Patienter som överlever ES eller OS har en måttligt ökat risk för drabbas av sekundära 
maligniteter. Riskökningen drivs till största delen av bröstcancer och gynekologiska 
maligniteter, men skiljer sig i övrigt åt mellan ES och OS vilket indikerar ett behov av 
skräddarsydd långvarig uppföljning. Risken för strålrelaterade komplikationer så som 
sekundär cancer får dock inte överskugga fördelarna med att ge strålbehandling för att 
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best orthopedic department in the world. You covered for me so that I could take my weeks 
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the manuscript afterwards. In the evenings we would watch Seinfeld and take sauna. How 
many professors serve PhDs in the department in such a way?  Lasse will be greatly missed. 
Emelie Styring, orthopaedic oncology surgeon in Lund, undisputed head of the Scandinavian 
Sarcoma Group (SSG) registry and co-author in two of the papers in this thesis. I´ve lost track 
of all the times I texted you and asked: “ to just check on some treatment details on a few 
patients”. Your reply was always immediate and contained all the information I needed, plus 
some extra information. Your valuable comments to the manuscripts were also a big help. 
The work that you do for SSG and the registry in particular is outstanding. In fact, if it 
weren´t for the quality of the registry facilitated through you, little of this work could have 
been done.  
Nina Jebsen, radiation oncologist at Haukeland University hospital in Bergen and co-author 
in two of my papers and a key player in the SSG. Your help by reviewing charts to obtain 
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always responded quickly and detailed, demonstrating great knowledge within the field of 
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thankful for.    
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in research and clinic, understand the value of collaboration, and you are very social. Thank 
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difference. 
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closely with every week. I have great respect for you as a person and for your knowledge and 
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